Form 4: Rapport Therapeutics Director Boosts Stake

Rapport Therapeutics Director Steven M. Paul increased his indirect beneficial ownership by acquiring 41,666 shares of common stock through Paul Capital Strategy III Fund LLC.

Summary

• Steven M. Paul, a Director and 10% Owner of Rapport Therapeutics, Inc. (RAPP), acquired a total of 41,666 shares of common stock.
• The transactions occurred on September 12, 2025, and were reported on September 15, 2025.
• The shares were acquired in two separate transactions through Paul Capital Strategy III Fund LLC.
• The first block of 28,284 shares was purchased at a weighted average price of $24.4996 per share, with prices ranging from $23.90 to $24.89.
• The second block of 13,382 shares was purchased at a weighted average price of $24.9712 per share, with prices ranging from $24.90 to $25.00.
• Following these transactions, Steven M. Paul indirectly beneficially owns 41,666 shares of common stock through Paul Capital Strategy III Fund LLC.
• The transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a director and 10% owner significantly increasing their stake in the company, indicating strong confidence in its future performance and valuation.

Positives

• A Director and 10% Owner increasing their stake signals strong confidence in the company's future prospects and valuation.
• The acquisition of shares through a Rule 10b5-1 plan indicates a pre-planned, systematic approach to increasing ownership, often reflecting a long-term positive outlook.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company, as it is a report of an insider transaction.

Industry Context

Insider buying, particularly by a director and significant owner, is often interpreted by the market as a positive signal, suggesting that those closest to the company believe its stock is undervalued or that significant positive developments are anticipated. This can be a stronger signal than purchases by other insiders, given the director's dual role as a 10% owner.

Corporate Governance

Related Party Transactions

• The acquisition of shares by Steven M. Paul, a Director and 10% Owner, through Paul Capital Strategy III Fund LLC, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this insider buying as a positive indicator of management confidence, potentially leading to increased investor interest and a positive impact on stock price.
• Employees and other stakeholders might interpret this as a sign of stability and positive future outlook for the company.

Key Dates

Recommendation

The significant purchase of common stock by a Director and 10% Owner, Steven M. Paul, signals strong insider confidence in Rapport Therapeutics. Such insider buying, especially when executed under a Rule 10b5-1 plan, suggests a belief that the company's shares are undervalued or that positive developments are on the horizon. This action typically serves as a bullish indicator for seasoned investors, warranting a 'buy' recommendation based on this filing.

Keywords

Rapport Therapeutics, RAPP, Insider Buying, Form 4, Director Purchase, Stock Acquisition, Steven M. Paul, Paul Capital Strategy III Fund LLC, 10b5-1 Plan